ResMed Inc Stock News

ResMed Inc. (NYSE:RMD ) Q1 2023 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO & Director Brett Sandercock

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Upgrades According to Credit Suisse, the prior rating for Hudson Pacific Properties Inc (NYSE:HPP) was changed from Underperform to Neutral. Hudson Pacific Properties earned $0.51 in the second quarte

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday,

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday, O

Upgrades For CME Group Inc (NASDAQ:CME), Deutsche Bank upgraded the previous rating of Hold to Buy. In the second quarter, CME Group showed an EPS of $1.97, compared to $1.64 from the year-ago quarte

Landec (LNDC) delivered earnings and revenue surprises of -166.67% and 1.89%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.

The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.

Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. See here the companies with upcoming ex-dividend dates and upcoming pay dates.

BARCELONA, Spain, Sept. 04, 2022 (GLOBE NEWSWIRE) -- Over 480 million people worldwide likely suffer from chronic obstructive pulmonary disease, or COPD, according to a late-breaking abstract led by

Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.

Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.

ResMed continues to offer compelling value after a robust set of fourth quarter earnings. RMD saw upsides at the top and bottom line relative to consensus, yet, the stock has been punished from August